TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
TRACON Pharmaceuticals, Inc. (TCON)
Last tracon pharmaceuticals, inc. earnings: 2/27 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
traconpharma.com
Company Research
Source: GlobeNewswire
The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary endpoint of 11% Company will focus on exploring strategic alternatives, that may include a variety of strategic transactions such as a reverse merger, acquisition, sale of all assets, or other strategic transactions leveraging its in-house Product Development Platform of CRO-independent clinical trial execution SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) today announced the objective response rate (ORR) by blinded independent central review (BICR) in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders), which is lower than the primary endpoint of the study of 11% ORR by BICR needed to support a biologics license application (BLA). As a result, the Company is terminating further development of envafolimab and is
Show less
Read more
Impact Snapshot
Event Time:
TCON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCON alerts
High impacting TRACON Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TCON
News
- TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform [Yahoo! Finance]Yahoo! Finance
- TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients [Yahoo! Finance]Yahoo! Finance
TCON
Earnings
- 5/14/24 - Miss
TCON
Analyst Actions
- 7/1/24 - HC Wainwright
TCON
Sec Filings
- 7/1/24 - Form 8-K
- 6/21/24 - Form 8-K
- 6/12/24 - Form 8-K
- TCON's page on the SEC website